N
NTLA icon

Natixis’s Intellia Therapeutics NTLA Stock Holding History

Natixis’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,045
Closed -$56.3K – 1101
2024
Q1 		$56.3K Sell
2,045
-189
-8% -$5.25K ﹤0.01% 818
2023
Q4 		$68.1K Sell
2,234
-967
-30% -$27.8K ﹤0.01% 801
2023
Q3 		$101K Buy
+3,201
New +$124K ﹤0.01% 784
2023
Q2 		– Sell
-3,668
Closed -$137K – 1102
2023
Q1 		$137K Sell
3,668
-146
-4% -$5.73K ﹤0.01% 774
2022
Q4 		$133K Sell
3,814
-349
-8% -$16.6K ﹤0.01% 857
2022
Q3 		$238K Sell
4,163
-198
-5% -$12.3K ﹤0.01% 961
2022
Q2 		$222K Sell
4,361
-700
-14% -$35.5K ﹤0.01% 1019
2022
Q1 		$368K Sell
5,061
-478
-9% -$40.5K ﹤0.01% 1030
2021
Q4 		$655K Sell
5,539
-584
-10% -$73.2K ﹤0.01% 986
2021
Q3 		$821K Sell
6,123
-43,885
-88% -$6.64M ﹤0.01% 930
2021
Q2 		$8.1M Sell
50,008
-211
-0.4% -$16.4K 0.04% 311
2021
Q1 		$4.03M Buy
50,219
+39,623
+374% +$2.66M 0.01% 557
2020
Q4 		$576K Buy
+10,596
New +$385K ﹤0.01% 881

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Natixis's NTLA Position: Q2 2024 in Review

Natixis sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 2,045 shares — an estimated $56.3K sold.

Natixis first reported a position in NTLA in Q4 2020 and held it in 13 quarters. The position peaked at $8.1M in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

  • Natixis reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Natixis sold 2,045 Intellia Therapeutics shares in Q2 2024, an estimated $56.3K.
  • Natixis first reported a position in Intellia Therapeutics in Q4 2020 and held it in 13 quarters.
  • Natixis's Intellia Therapeutics position peaked at $8.1M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.